FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8. doi: 10.1007/s00259-005-0040-z. Epub 2006 Mar 21.

Abstract

Purpose: The purpose of this study was to evaluate the impact of FDG-PET following chemoradiotherapy (CRT) on treatment planning and survival in patients with oesophageal cancer (OC).

Methods: Fifty-three consecutive OC patients had a post-treatment PET scan to evaluate tumour response to CRT prior to possible surgery. Baseline pre-CRT PET was performed in 33 patients. Prospectively recorded post-CRT management plans were compared with post-PET treatment. High impact was defined as a change in treatment intent or modality. Survival was analysed using the Kaplan-Meier product limit method and Cox proportional hazards regression model.

Results: After completion of CRT, 23/53 patients (43%) achieved complete metabolic response (CMR), as compared with only four (8%) with complete response on computed tomography. High PET impact was observed in 19 patients (36%). CMR was strongly predictive of survival (p<0.008) on multivariate analysis. CMR patients in whom resection was not performed had comparable survival to those (CMR and non-CMR) who underwent resection.

Conclusion: The use of post-treatment FDG-PET for assessment of tumour response after CRT changed the clinical management of more than one-third of OC patients. CMR status as assessed by PET powerfully stratified prognosis. Even in the absence of a baseline study, normalisation of uptake at all sites of known tumoral involvement carries a good medium-term prognosis.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Australia / epidemiology
  • Combined Modality Therapy / statistics & numerical data
  • Drug Therapy / statistics & numerical data
  • Esophageal Neoplasms / diagnostic imaging*
  • Esophageal Neoplasms / mortality*
  • Esophageal Neoplasms / therapy
  • Fluorodeoxyglucose F18*
  • Humans
  • Middle Aged
  • Outcome Assessment, Health Care / methods*
  • Outcome Assessment, Health Care / statistics & numerical data
  • Positron-Emission Tomography / methods
  • Positron-Emission Tomography / statistics & numerical data*
  • Prevalence
  • Prognosis
  • Radiopharmaceuticals
  • Radiotherapy / statistics & numerical data
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Survival Analysis
  • Survival Rate
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18